TPN-101, 400 mg/day

DRUG2 trials

Sponsors

Transposon Therapeutics, Inc.

Conditions

Amyotrophic Lateral SclerosisFrontotemporal DementiaProgressive Supranuclear Palsy

Phase 2

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

CompletedNCT04993768

Transposon Therapeutics, Inc.Progressive Supranuclear Palsy

Start: 2021-12-12End: 2024-03-24Updated: 2026-04-08

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

CompletedNCT04993755

Transposon Therapeutics, Inc.Amyotrophic Lateral Sclerosis, Frontotemporal Dementia

Start: 2021-10-01End: 2023-09-01Updated: 2026-04-03

Related Papers

A Phase IIa clinical trial to evaluate the effects of anti-retroviral therapy in Alzheimer’s disease (ART-AD)

npj Dementia2025-03-1210 citations